PMN ProMIS Neurosciences Inc.

P/E --
Forward P/E --
Price/Sales 4016.22
Beta -0.222
Div Yield --
Market Cap --

Company Analysis

Latest News

🟢 ProMIS Neurosciences is trading 5% up today in a technical rebound following recent profit-taking

ProMIS Neurosciences is trading at $14.42 (up 5%) in what appears to be a continuation of a technical rebound following sharp recent swings and...

🟢 ProMIS Neurosciences is trading 15% up today in a technical rebound after recent volatility

ProMIS Neurosciences is trading 15% up at $15.78 in pre-market, extending a sharp rebound after recent volatility and profit-taking. - The move follows prior...

🟢 ProMIS Neurosciences is trading 7.6% up today in a technical rebound from recent weakness

ProMIS Neurosciences is trading at $14.76 (up 7.6%) in pre-market action, rebounding from a period of profit-taking and broader biotech sector weakness seen on...

🔴 ProMIS Neurosciences is trading 5.1% down today on profit-taking and biotech sector weakness

ProMIS Neurosciences is trading 5.1% down at $14.16 as investors lock in gains following a sharp multi-day rally and a broader decline in the biotech...

🟢 ProMIS Neurosciences is trading 7% up today amid a broad risk-on rally in U.S. equities

ProMIS Neurosciences is trading 7% up today at $15.05 as the stock rebounds from recent volatility and follows a broad risk-on rally in U.S. equities. • The...

🟢 ProMIS Neurosciences is trading 6.7% up today as it rebounds amid improving broader risk sentiment

ProMIS Neurosciences is trading at $15.00 (6.7%) up today, rebounding from recent volatility and a sharp gain on July 28 despite a lack of fresh...

🟢 ProMIS Neurosciences is trading 12.8% up today on favorable interim Phase 1b data for Alzheimer’s drug PMN310

ProMIS Neurosciences is trading 12.8% up now at $12.88 after releasing favorable six-month interim data from its PRECISE-AD Phase 1b trial of Alzheimer’s drug...

ProMIS Neurosciences Reports Favorable Interim Phase 1b Data for Alzheimer's Drug PMN310

ProMIS Neurosciences Reports Favorable Interim Phase 1b Data for Alzheimer's Drug PMN310

ProMIS Neurosciences announced positive blinded six-month interim safety and biomarker data from its PRECISE-AD Phase 1b clinical trial evaluating PMN310 in...

🟢 ProMIS Neurosciences is trading 15.8% up today after bullish analyst coverage and upcoming webinar on clinical trial data

• Chardan initiated coverage with a Buy rating and a $20 price target on July 27, sparking investor interest. • The company is also set to host a webinar...

ProMIS Neurosciences Surges 12.7% on Chardan's Buy Call — But Can a Micro-Cap Biotech With No Revenue Justify a $20 Target?

ProMIS Neurosciences Surges 12.7% on Chardan's Buy Call — But Can a Micro-Cap Biotech With No Revenue Justify a $20 Target?

Shares of ProMIS Neurosciences jumped 12.7% to $13.21 after Chardan initiated coverage with a Buy rating and a $20 price target, snapping a brutal five-session...

🟢 ProMIS Neurosciences is trading 12.7% up today after Chardan initiated coverage with a Buy rating and $20 price target

ProMIS Neurosciences is trading 12.7% up at $13.21 following a sharp after-hours relief bounce triggered by a Buy rating initiation from Chardan. • Chardan...

🟢 ProMIS Neurosciences is trading 9% up today in a relief bounce after Chardan initiated coverage with a Buy rating

ProMIS Neurosciences is trading at $12.78 (9% up) in after-hours trading as shares stage a relief bounce following a recent Buy rating from Chardan. - Chardan...

🔴 ProMIS Neurosciences is trading 5.7% down today despite Chardan initiating coverage with a Buy rating.

• ProMIS Neurosciences is trading at $11.50 (-5.74%) today. • Chardan initiated coverage on PMN with a "Buy" rating and a $20.00 price target, suggesting...

🔴 ProMIS Neurosciences is trading 6% down today as traders unwind recent volatility-driven gains

ProMIS Neurosciences is trading 6% down today at $11.90 as the stock undergoes a technical pullback following a sharp multi-day rebound. • The decline follows...

🟢 ProMIS Neurosciences is trading 10.1% up today in a technical rebound

ProMIS Neurosciences is trading 10.1% up at $13.88 as the stock stages a technical rebound following recent volatility. • The move reverses a significant...

🟢 ProMIS Neurosciences is trading 14.2% up today despite no clear company-specific catalyst

ProMIS Neurosciences is trading at $14.40 (+14.20%) in pre-market following a sharp overnight gap, despite a lack of company-specific news, earnings updates,...

🔴 ProMIS Neurosciences is trading 10.6% down

ProMIS Neurosciences is trading at $12.50, down 10.6% from a comparison close of $13.99 during regular trading. This is a price-action follow-up, so a separate...

🔴 ProMIS Neurosciences is trading 5.4% down today on profit-taking after last week's Alzheimer's data rally

ProMIS Neurosciences is trading 5.4% down at $14.26 today, appearing to undergo profit-taking and consolidation following a sharp multi-day rally. • The...

🟢 ProMIS Neurosciences is trading 6.6% up today on positive Alzheimer’s trial data

ProMIS Neurosciences is trading 6.6% up at $16.20 today, extending a multi-day rally following positive clinical updates for its Alzheimer’s treatment...

🟢 ProMIS Neurosciences is trading 10.4% up

ProMIS Neurosciences is trading at $14.68, up 10.4% from a comparison close of $13.30 during regular trading. This is a price-action follow-up, so a separate...